- Analyst firm Wedbush maintains an “Outperform” rating, citing International Business Machines (NYSE:IBM)‘s involvement in U.S. quantum initiatives as a significant growth driver.
- IBM is partnering with the U.S. Commerce Department to build “Anderon,” America’s first pure-play quantum foundry, with a joint investment of $2 billion, partially funded by the 2022 CHIPS Act.
- Following the news, IBM’s stock experienced a significant rally, climbing 11.3% and reversing a previous 23% year-to-date decline.
International Business Machines (NYSE:IBM) is a major player in the enterprise technology sector. The company provides a wide range of hardware, software, and consulting services. It competes with other established tech firms like Oracle, Cisco Systems, and Hewlett Packard Enterprise. Recently, IBM’s stock performance had been lagging behind its peers.
On May 21, 2026, analyst firm Wedbush confirmed its “Outperform” rating for IBM. At the time, the stock price was $243.75. As highlighted by TheFly, Wedbush sees IBM’s involvement in U.S. quantum initiatives as a significant new growth driver for the company and the broader industry.
This positive outlook is supported by a major announcement. IBM is partnering with the U.S. Commerce Department to build “Anderon,” which is described as America’s first pure-play quantum foundry. Both IBM and the government will invest $1 billion each into the project, with federal funds coming from the 2022 CHIPS Act.
The investment is part of a larger government effort to boost the U.S. quantum supply chain. As reported by GuruFocus, the administration announced a $2 billion investment across nine companies. IBM is a primary recipient, set to receive $1 billion to establish a new company focused on quantum computer chips.
Following the news, IBM’s stock experienced a significant rally, climbing 11.3% as noted by The Motley Fool. The stock price reached $252.97, a gain of 12.43%, with a daily trading volume of 25.05 million shares. This surge marks a sharp reversal from its previous 23% year-to-date decline.
